# Immune and Genomic Markers in ALK+ NSCLC

> **NCT04881916** · — · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Anaplastic Lymphoma Kinase Gene Translocation
- Non-Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04881916
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04881916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04881916, "Immune and Genomic Markers in ALK+ NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04881916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*